Ryvu Therapeutics S.A.
$14.00▼ 1.82%($-0.26)
TickerSpark Score
41/100
▌ Weak
47
Valuation
20
Profitability
35
Growth
72
Health
30
Momentum
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RVU.WA research report →
52-Week Range2% of range
Low
$13.64
Current
$14.00
High
$32.50
Company Overviewwww.ryvu.com
About the company
Ryvu Therapeutics S. A. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing novel small molecule treatments for oncology.
- CEO
- Pawel Tadeusz Przewiezlikowski
- IPO
- 2011
- Employees
- 328
- HQ
- Kraków, PL
Price Chart
-54.10% · this period
Valuation
- Market Cap
- $323.68M
- P/E
- -3.58
- P/S
- 5.20
- P/B
- 7.83
- EV/EBITDA
- -4.09
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -47.74%
- Op Margin
- -151.41%
- Net Margin
- -142.28%
- ROE
- -135.46%
- ROIC
- -62.87%
Growth & Income
- Revenue
- $62.25M · -20.15%
- Net Income
- $-101,229,000 · 9.16%
- EPS
- $-4.38 · 9.13%
- Op Income
- $-122,153,000
- FCF YoY
- 13.02%
Performance & Tape
- 52W High
- $32.50
- 52W Low
- $13.64
- 50D MA
- $20.12
- 200D MA
- $24.44
- Beta
- 0.40
- Avg Volume
- 47.97K
Get TickerSpark's AI analysis on RVU.WA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Coverage · RVU.WA
Our RVU.WA coverage
Recent articles, reports, and earnings notes.
On-Demand Research
No research on RVU.WA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RVU.WA report →Internal Compare
Similar companies
Peers in the same neighborhood.